NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as...
14 insider purchases on record · latest filing 2026-09-15.
Insiders have also filed 82 sale transactions at NAMS.